Comparative study of telmisartan tablets prepared via the wet granulation method and Pritor™ prepared using the spray-drying method

Archives of Pharmacal Research

Volumn 34, Issue 3, 2011, Pages 463-468

  Park, Junsung ^a   Park, Hee Jun ^a   Cho, Wonkyung ^a   Cha, Kwang Ho ^a   Yeon, Wonki ^a   Kim, Min Soo ^a   Kim, Jeong Soo ^a   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

Author keywords

Amorphous; Pritor ; Spray drying; Telmisartan; Wet granulation

Indexed keywords

TELMISARTAN;

ARTICLE; CHEMICAL PROCEDURES; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; IN VITRO STUDY; SPRAY DRYING; TABLET; TABLET FRIABILITY; TABLET HARDNESS; TABLET PROPERTY; WATER ABSORPTION; WET GRANULATION; X RAY DIFFRACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG STABILITY; HARDNESS; HYDROGEN-ION CONCENTRATION; SOLUBILITY; TABLETS; WETTABILITY; X-RAY DIFFRACTION;

EID: 79959933369     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0315-9     Document Type: Article

References (21)

1. Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., and Kurtz, T. W., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARmodulating activity. Hypertension, 43, 993-1002 (2004). (Pubitemid 38579904)
2. Chauhan, B., Shimpi, S., and Paradkar, A., Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur. J. Pharm. Sci., 26, 219-230 (2005). (Pubitemid 41169805)
3. FDA, Guidance for industry: immediate release solid oral dosage forms - scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro dissolution testing, and in vivo bioequivalance documentation. In research, C. F. D. E. A. (Ed.). Rockville, MD (November, 1995).
4. FDA, Center for drug evaluation and research, guidance for industry: dissolution testing of immediate release solid oral dosage forms. In research, C. F. D. E. A. (Ed.). Rockville, MD (August, 1997a).
5. FDA, Center for drug evaluation and research, guidance for industry: supac-mr: modified release solid oral dosage forms - scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro dissolution testing, and in vivo bioequivalance documentation. In research, C. F. D. E. A. (Ed.). Rockville, MD (September, 1997b).
6. FDA, Center for drug evaluation and research, guidance for industry: waiver of in vitro bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. In research, C. F. D. E. A. (Ed.). Rockville, MD (August, 2000a).
7. FDA, Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products General considerations. In research, C. F. D. E. A. (Ed.). Rockville, MD (October, 2000b).
8. Friedel, T. and Schepky, G., Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof. In organization, W. I. P. (Ed.). US2009/0227802, A61K 9/20 (2009).
9. Gordon, M. S., Rudraraju, V. S., Dani, K., and Chowhan, Z. T., Effect of the mode of super disintegrant incorporation on dissolution in wet granulated tablets. J. Pharm. Sci., 82, 220-226 (1993). (Pubitemid 23147756)
10. Hancock, B. C. and Parks, M., What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res., 17, 397-404 (2000). (Pubitemid 30395293)
11. Hwang, S.-J., Park, J., Cho, W., Cha, K.-H., and Lee, B., Preparation method of tablet containing telmisartan using wet granulation. In office, K. I. P. (Ed.). KR 10-0960953 (2009).
12. Leuner, C. and Dressman, J., Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50, 47-60 (2000). (Pubitemid 30326688)
13. Löbenberg, R. and Amidon, G. L., Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm., 50, 3-12 (2000). (Pubitemid 30326685)
14. Moore, J. W. and Flanner, H. H., Mathematical comparison of dissolution profiles. Pharm.Technol., 20, 64-74 (1996). (Pubitemid 126450495)
15. Palaparthi, U. D., Rout, A. J., and Arumalla, M. R., Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide. In organization, W. I. P. (Ed.). PCT/ US2008/081714 (2008).
16. Stangier, J., Su, C. A. P. F., and Roth, W., Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res., 28, 149-167 (2000). (Pubitemid 30648951)
17. Thomas, R. and Maerz, F., Pharmaceutical composition. In organization, W. I. P. (Ed.). PCT/EP2008/053009 (2008).
18. Thybo, P., Pedersen, B. L., Hovgaard, L., Holm, R., and Müllertz, A., Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Pharm. Dev. Technol., 13, 375-386 (2008).
19. Tran, P. H. L., Tran, H. T. T., and Lee, B.-J., Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J. Control. Release, 129, 59-65 (2008).
20. Van Den Mooter, G., Weuts, I., De Ridder, T., and Blaton, N., Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int. J. Pharm., 316, 1-6 (2006). (Pubitemid 43765697)
21. Zhao, N. and Augsburger, L. L., The Influence of granulation on super disintegrant performance. Pharm. Dev. Technol., 11, 47-53 (2006).